Free Trial
NASDAQ:VVOS

Vivos Therapeutics (VVOS) Stock Price, News & Analysis

Vivos Therapeutics logo
$2.29 +0.02 (+0.88%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$2.38 +0.09 (+3.89%)
As of 05/28/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Vivos Therapeutics Stock (NASDAQ:VVOS)

Key Stats

Today's Range
$2.24
$2.45
50-Day Range
$2.08
$3.71
52-Week Range
$1.91
$6.28
Volume
77,297 shs
Average Volume
455,678 shs
Market Capitalization
$13.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.82
Consensus Rating
Moderate Buy

Company Overview

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

Vivos Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

VVOS MarketRank™: 

Vivos Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 813th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Vivos Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Vivos Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Vivos Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Vivos Therapeutics are expected to grow in the coming year, from ($1.79) to ($1.43) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Vivos Therapeutics is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Vivos Therapeutics is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Vivos Therapeutics has a P/B Ratio of 10.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Vivos Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    4.49% of the float of Vivos Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Vivos Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Vivos Therapeutics has recently decreased by 20.59%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Vivos Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Vivos Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.49% of the float of Vivos Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Vivos Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Vivos Therapeutics has recently decreased by 20.59%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Vivos Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Vivos Therapeutics this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Vivos Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.00% of the stock of Vivos Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 26.35% of the stock of Vivos Therapeutics is held by institutions.

  • Read more about Vivos Therapeutics' insider trading history.
Receive VVOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vivos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VVOS Stock News Headlines

White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
See More Headlines

VVOS Stock Analysis - Frequently Asked Questions

Vivos Therapeutics' stock was trading at $4.29 at the start of the year. Since then, VVOS stock has decreased by 46.6% and is now trading at $2.29.
View the best growth stocks for 2025 here
.

Vivos Therapeutics, Inc. (NASDAQ:VVOS) released its quarterly earnings results on Thursday, May, 15th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.01. The business earned $3.70 million during the quarter, compared to the consensus estimate of $3.63 million. Vivos Therapeutics had a negative trailing twelve-month return on equity of 335.04% and a negative net margin of 86.19%.
Read the conference call transcript
.

Vivos Therapeutics shares reverse split on Friday, October 27th 2023. The 1-25 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Vivos Therapeutics (VVOS) raised $20 million in an initial public offering on Friday, December 11th 2020. The company issued 3,300,000 shares at a price of $5.00-$7.00 per share. Roth Capital Partners acted as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers.

Top institutional investors of Vivos Therapeutics include Cutter & CO Brokerage Inc. (0.83%) and EWA LLC (0.18%).
View institutional ownership trends
.

Shares of VVOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vivos Therapeutics investors own include Meta Platforms (META), NIO (NIO), Pfizer (PFE), Plug Power (PLUG), Advanced Micro Devices (AMD), Aridis Pharmaceuticals (ARDS) and Cocrystal Pharma (COCP).

Company Calendar

Last Earnings
5/15/2025
Today
5/28/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:VVOS
Fax
N/A
Employees
160
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.82
High Stock Price Target
$6.20
Low Stock Price Target
$2.25
Potential Upside/Downside
+110.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$13.58 million
Pretax Margin
-86.19%

Debt

Sales & Book Value

Annual Sales
$14.63 million
Price / Cash Flow
N/A
Book Value
$0.22 per share
Price / Book
10.41

Miscellaneous

Free Float
5,713,000
Market Cap
$13.49 million
Optionable
Optionable
Beta
7.31
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (NASDAQ:VVOS) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners